SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending following a significant sell-off ignited by the recent disclosure of Nvidia's historical exit from its stock. This has polarized investors, with many dismissing the market reaction as headline-driven noise, pointing to APLD's robust fundamentals, continued institutional accumulation, and impending announcements of new hyperscaler contracts, in addition to its strategic cloud business spin-off.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as a major institutional re-purchase of shares, coupled with its recent FDA Fast Track designation, fuels community discussions about its significant undervaluation and potential for a short squeeze. High anticipation surrounds its upcoming Investor Day, where updates on its "best-in-class" nanobody pipeline and regulatory pathway for inflammatory diseases are expected to clarify its future.

Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Aldeyra Therapeutics Inc

Aldeyra Therapeutics is trending as the lack of communication regarding its Reproxalap proposed label following the February 16 deadline, coupled with its CDO's recent resignation and ongoing fraud lawsuits, leads bears to anticipate a third Complete Response Letter by March 16, while bulls view the FDA's earlier sharing of a draft label as a strong indicator of eventual approval.

Palo Alto Networks, Inc. engages in the provision of network security solutions to enterprises, service providers, and government entities. It operates through the following geographical segments: the United States, Israel, and Other Countries. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

Palo Alto Networks is trending amidst a sharp post-earnings sell-off, driven by a lowered fiscal 2026 profit outlook and soft Q3 EPS guidance despite strong revenue growth. The community actively debates if this market reaction is an overcorrection due to acquisition-related margin impacts and general AI concerns impacting the software sector, or a necessary re-evaluation of its premium valuation.

Fiverr International Ltd. develops an e-commerce platform that allows people to buy and sell digital services. It operates through the following geographical segments: U.S., Europe, Asia Pacific, Rest of the World and Israel. The firm offers digital marketing, graphics and design, video and animation, writing and translation, and music and audio. The company was founded by Micha Kaufman and Shai Wininger in 2009 and is headquartered in Tel Aviv, Israel.

Fiverr International Ltd

Fiverr is trending after its recent earnings report included a weaker-than-expected FY26 revenue outlook and a strategic restructuring aiming to become an "AI-native" company. This has split community sentiment, with some viewing AI as an existential threat to the gig economy and others seeing deep undervaluation in a profitable company adapting for future growth.

Perion Network Ltd. is a global technology company helping brands, agencies, and retailers drive better results from their marketing investments. Through the Perion One platform, the company delivers advanced, AI-powered solutions across the entire digital media ecosystem. Perion One makes digital advertising more effective by continuously connecting the dots between data, creative, and media channels. With proprietary technologies such as SORT for cookieless targeting, AI-based custom algos for campaign optimization, high-impact creative formats, and real-time insights, Perion enables smarter, more adaptive advertising at scale. The company was founded by Ofer Adler and Yaron Adler in November 1999 and is headquartered in Tel Aviv, Israel.

Perion Network Ltd.

Perion Network Ltd

Perion Network is trending due to a significant guidance cut after Microsoft Bing's decision to exclude several publishers from its search distribution marketplace, fueling intense debate over the company's future growth and management despite its substantial cash reserves and active share repurchase program.

Travel + Leisure Co. engages in the provision of hospitality services and travel products. It operates through the Vacation Ownership and Travel and Membership segments. The Vacation Ownership segment is involved in developing, marketing, and selling vacation ownership interests to individual consumers, providing consumer financing in connection with the sale of vacation ownership interests, and providing property management services at resorts. The Travel and Membership segment focuses on the operations of travel businesses, including three vacation exchange brands, travel technology platforms, travel memberships, and direct-to-consumer rentals. The company was founded in 1990 and is headquartered in Orlando, FL.

Travel+Leisure Co

Travel+Leisure Co. is trending after reporting stronger-than-expected earnings and providing an optimistic outlook, which is driving analyst upgrades and enthusiastic discussions around the company's new share repurchase program and proposed dividend increase, signaling confidence in the resilient leisure travel sector.

HF Sinclair Corp. is an independent energy company. It manufactures and sells products such as gasoline, diesel fuel, jet fuel, renewable diesel, specialty lubricant products, specialty chemicals, and specialty and modified asphalt. The company operates through five segments: Refining, Marketing, Renewables, Lubricants and Specialty Products, and Midstream. The company was founded in 1947 and is headquartered in Dallas, TX.

HF Sinclair Corp.

HF Sinclair Corporation

HF Sinclair is trending as investors digest a strong beat on adjusted Q4 earnings and revenue, alongside the unexpected announcement that CEO Tim Go is taking a voluntary leave of absence and the Board's Chairperson has stepped in as interim leader. The community is actively discussing these contrasting developments, weighing the company's financial performance against the sudden leadership transition and its broader positioning in the refining sector.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion ($INFQ) is gaining significant market attention as it begins trading after its de-SPAC merger, with investors actively discussing its commercialized neutral-atom quantum technology and strategic partnerships, including with NASA and NVIDIA, positioning it as an undervalued leader compared to other quantum peers.

Global-e Online Ltd. engages in the provision of cross-border e-commerce solutions. It offers Global-e Pro and Global-e enterprise. The firm enables merchants to increase the conversion of international traffic into sales by providing online shoppers across global destinations with a seamless, localized shopping experience. Global-e Online was founded by Shahar Tamari, Amir Schlachet, and Nir Debbi on February 21, 2013 and is headquartered in Petach Tikva, Israel.

Global E Online Ltd

Global-E Online is trending as robust Q4 earnings significantly surpassed expectations, coupled with raised future guidance, fuels community optimism about its strong performance and pivotal role in expanding cross-border e-commerce, notably through its deepening Shopify partnership.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Sees Significant Increase in Short Interest

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) was the recipient of a significant increase in short interest during the month of January. As of January 30th, there was short interest...

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Given Average Rating of "Moderate Buy" by Brokerages

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the six ratings firms that are currently covering the company...

Acumen Pharmaceuticals (NASDAQ:ABOS) Rating Lowered to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Acumen Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday...

Acumen Pharmaceuticals (NASDAQ:ABOS) Price Target Raised to $7.00 at BTIG Research

BTIG Research boosted their price objective on shares of Acumen Pharmaceuticals from $4.00 to $7.00 and gave the company a "buy" rating in a research note on Tuesday...

Acumen Pharmaceuticals (NASDAQ:ABOS) CFO Sells $12,536.16 in Stock

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) CFO Matt Zuga sold 6,888 shares of the stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of...

Insider Selling: Acumen Pharmaceuticals (NASDAQ:ABOS) CFO Sells 6,888 Shares of Stock

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) CFO Matt Zuga sold 6,888 shares of Acumen Pharmaceuticals stock in a transaction dated Thursday, January 8th. The shares were sold at an...

Acumen Pharmaceuticals (NASDAQ:ABOS) CEO Sells $14,820.26 in Stock

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) CEO Daniel Joseph Oconnell sold 8,143 shares of the stock in a transaction on Thursday, January 8th. The shares were sold at an average...

Acumen Pharmaceuticals (NASDAQ:ABOS) CEO Daniel Joseph Oconnell Sells 12,941 Shares

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) CEO Daniel Joseph Oconnell sold 12,941 shares of the business's stock in a transaction that occurred on Friday, January 9th. The stock was...

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) have earned an average rating of "Moderate Buy" from the five research firms that are presently covering the company...

James Doherty Sells 6,467 Shares of Acumen Pharmaceuticals (NASDAQ:ABOS) Stock

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) insider James Doherty sold 6,467 shares of the company's stock in a transaction on Thursday, January 8th. The stock was sold at an average...

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages and develops medicines and diagnostics for Alzheimer's disease. The company was founded by William L. Klein, Grant A. Krafft, and Caleb Finch in 1996 and is headquartered in Newton, MA.

Acumen Pharmaceuticals Inc

Fundamental

Technical

A mix of both

Some investors focus on company fundamentals like earnings, growth, and valuation. Others rely on price action, trends, and momentum. Many use a combination of both to guide their decisions. What do you use?

What type of analysis drives your investment decisions?

Current Price	$2.45
Prev Close	$2.51
Open	$2.50
Dividend Yield	0.00%
50-Day Moving Average	$2.14
Beta	1.59
Avg. Volume	1.29M
PE Ratio	-1.14

52-Week High	$3.05
52-Week Low	$0.8551
Market Capitalization	$152.04M
EPS (Annual)	-$1.71
Price to Book	1.63
Revenue Per Employee	$0.00

ABOS
Acumen Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ABOS News

ABOSAcumen Pharmaceuticals Inc